Transmedics Group Inc Dossier - Source-backed chat

Transmedics Group Inc

TMDXNASDAQ

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)1.60

Intrinsic Value $46.38median of 4 methods · middle span $20-$72based on filings through 30 Jun 2026

Market Price $83.45Price as of 30 Sep 2026

OvervaluedIntrinsic value is 44% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $2.9B

Enterprise Value $2.9B

Shares Outstanding 36.3M diluted

Moat Rating Narrow

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

TransMedics Group, Inc. is the undisputed leader in portable extracorporeal warm perfusion and assessment of donor organs. Despite a sharp post-earnings sell-off following Q1 2026 results due to margin compression and clinical trial enrollment delays, the long-term growth narrative remains highly compelling. The company's vertically integrated National OCS Program (NOP), supported by a dedicated fleet of 22 owned aircraft, creates a powerful competitive moat. Near-term margin pressure is a reflection of front-loaded strategic investments in logistics, R&D, and international expansion rather than structural deterioration. Reaffirming full-year 2026 revenue guidance of $727M to $757M (20% to 25% YoY growth) highlights management's confidence in sustained demand.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$65.00

Mean target$97.30

High · most bullish analyst$125.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$65.0015%

The U.S. Transplant Modernization Act causes prolonged disruptions to OPO performance, and competitive pressures continue to stall clinical trial enrollments. High capital expenditures and operating costs from the aviation fleet lead to persistent free cash flow deficits and further margin compression, keeping the stock range-bound.

Base CaseCentral scenario

$97.3060%

Matches the consensus mean

TransMedics steadily resolves clinical trial enrollment delays for ENHANCE and DENOVO, while maintaining its 20% to 25% revenue growth trajectory for 2026. Operating margins remain pressured in the near term (up to 250 bps below 2025 levels) but stabilize as fleet utilization remains high at ~82% of NOP missions. Valuation multiples recover to historical averages as execution risks subside.

Bull CaseUpside scenario

$125.0025%

Rapid international expansion (particularly the launch of the European transplant logistics network via PAD Aviation) and swift regulatory clearance of the CHOPS platform accelerate top-line growth. Operating leverage from the aviation fleet materializes faster than expected, driving gross margins back above 60% and operating margins toward 20% by late 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Unrivaled technology platform as the only FDA-approved portable, multi-organ, warm perfusion system.
Strong competitive moat established through a vertically integrated logistics network with 22 owned aircraft.
Robust balance sheet with $461.7 million in cash and cash equivalents to fund ongoing growth initiatives.
Reiterated full-year 2026 revenue guidance of $727M to $757M, representing solid 20% to 25% growth.

Key Investment Risks

Near-term margin compression due to heavy investments in logistics, R&D, and international infrastructure.
Enrollment delays in critical ENHANCE and DENOVO clinical trials due to competitive dynamics.
Regulatory and operational complexities associated with managing a growing aviation fleet.
Transient negative impacts from the U.S. Transplant Modernization Act on donor organ availability.

Thesis Invalidation Triggers

A downward revision of the full-year 2026 revenue guidance below $727 million.
Failure to secure regulatory clearance or successfully launch the CHOPS platform.
Persistent negative free cash flow that severely depletes the company's cash reserves.
A structural decline in NOP fleet utilization below 75%.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.